60  mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

Ticagrelor is a new novel, reversibly binding, direct-acting P2Y12 receptor antagonist. When compared with clopidogrel, ticagrelor had a more potent and more predictable antiplatelet aggregation effect. Current guidelines recommend that ticagrelor 90  mg twice daily was superior to clopidogrel 75 mg once daily in coronary artery disease (CAD) patients [1]. However, increasing evidence showed ticagrelor increased the risk of bleeding, dyspnea and bradycardia [2–3], indicating that lower doses of ticagrelor could be a good option for patient s with CAD.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research